Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$266.3MCash on Hand
32.3mo Cash Runway
Follow ENGN by emailGet an email when ENGN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ENGN, unsubscribe in one click. Privacy
📣 What ENGN Says Is Next
2H 2026 · “LEGEND Cohorts 2a, 2b and 3: As part of cash conservation efforts, the Company has stopped enrollment in these additional cohorts and plans to reevaluate its strategy for them following discussion with the FDA in 2H 2026.”
Company press release, Jun 15, 2026 · SEC filing
second half of 2026 · ““Feedback from the urology community on the emerging detalimogene without surfactant profile, presented at the AUA meeting in May, supports our plan to await mature durability data in the second half of 2026 and meet with the FDA about initiating a BLA submission for detalimogene before year end,” said Ron Cooper, President and Chief Executive Officer, enGene.”
Company press release, Jun 15, 2026 · SEC filing
second half of 2026 · “The Company plans further engagement with the FDA as it approaches a potential Biologics License Application (BLA) filing and plans to provide an update in the second half of 2026.”
Company press release, May 7, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Clinical trial Announced results from pivotal Cohort 1 of the Phase 2 LEGEND trial of detalimogene and alignment with the FDA on key components of the planned Biologics License Application. Preliminary cash, cash equivalents and marketable securities of approximately $245.8 million as of October 31, 2026, unaudited by KPMG. Form 8-K · SEC filing · Press release
Sep 8, 2026 ·
Earnings Reported Q3 results for the quarter ended July 31, 2026, with a net loss of $32.5 million ($0.47 per share) versus $29.0 million ($0.57 per share) a year earlier, and $266.3 million in cash, equivalents and marketable securities. Form 8-K · SEC filing · Press release
Sep 8, 2026 ·
Quarterly report for the period ended Jul 31, 2026 Form 10-Q · SEC filing
Aug 11, 2026 ·
enGene hosted a virtual key opinion leader event on August 11, 2026 covering non-muscle invasive bladder cancer market research insights, with the slide presentation filed as Exhibit 99.1. The filing itself reports no new trial results or financial figures. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Apr 2028 · Phase 1/2 · Recruiting · LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
ENGN holds $266.3M in cash and short-term investments (as of Jul 31, 2026) and burns about $24.7M/quarter from operations,
an estimated runway of 32.3 months at that rate (BioRadar estimate, not company guidance).
Share count 67,016,316 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full ENGN picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ENGN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.